PRESS RELEASES

Found 234 Results
Page 1 of 24

Onxeo Will Publish Its Annual Results on April 17, 2020


The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]

Tags:

03/27/2020

Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020


Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

02/27/2020

Onxeo Enters into Settlement Agreement with SpePharm and SpeBio


Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]

Tags:

02/11/2020

“La France bouge” – Europe 1 : Interview of Judith Greciet


(in French only)   Watch the interview  

Tags:

02/04/2020

Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer


The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]

Tags:

01/29/2020

Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020


Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

01/28/2020

Onxeo Publishes Shareholder Newsletter


Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

01/20/2020

Onxeo Announces its Financial Agenda for 2020


  Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]

Tags:

12/09/2019

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology


In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]

Tags:

11/13/2019

Page 1 of 24
Onxeo Will Publish Its Annual Results on April 17, 2020
03/27/2020
Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020
02/27/2020
Onxeo Enters into Settlement Agreement with SpePharm and SpeBio
02/11/2020
Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer
01/29/2020
Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020
01/28/2020
Onxeo Publishes Shareholder Newsletter
01/20/2020
Onxeo Announces its Financial Agenda for 2020
12/09/2019
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
11/13/2019
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
11/05/2019
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
11/04/2019

Last updated on